ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 212

Rising Incidence and Prevalence of Gout in the Canadian General Population

Sharan K. Rai1, J Antonio Avina-Zubieta2, Natalie McCormick3, Mary De Vera4, Kamran Shojania5, Eric C. Sayre6 and Hyon K. Choi7, 1Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, 2University of British Columbia, Vancouver, BC, Canada, 3Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, 4Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, 5Rheumatology, University of British Columbia, Vancouver, BC, Canada, 6Arthritis Research Canada, Richmond, BC, Canada, 7Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: gout and population studies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Metabolic and Crystal Arthropathies Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:
Gout is increasingly becoming recognized as the
most common form of inflammatory arthritis worldwide; however, no Canadian
general population-based data on the disease burden of gout are available. We
estimated the incidence and prevalence of gout in an entire Canadian province (British
Columbia, BC) from 1997-2012.

Methods:
We utilized Population Data BC, an administrative database spanning the
province of BC (approximately 4.5 million individuals) that includes all
outpatient visits and hospital admissions from 1990-2012. The primary case
definition of gout was at least one recorded diagnosis of gout (ICD-9-CM 274 or
ICD-10-CA M10) at either a physician or hospital visit. We additionally
explored secondary definitions of gout using available detailed medication
dispensation information (obtained from BC PharmaNet), including individuals
with at least two recorded diagnoses of gout or at least one recorded diagnosis
of gout plus at least one dispensation of anti-gout medication (i.e.,
allopurinol, febuxostat, probenecid, or colchicine). To ensure incident gout
cases, we required all newly diagnosed individuals to have at least five years
prior without any record of a gout diagnosis. Annual incidence and prevalence
estimates were age-sex-standardized using 2012 as the reference. Annual
population estimates were obtained from BC Stats.

Results:
Of 4,542,508 individuals in BC in 2012, we identified 173,003 prevalent gout
cases (68% male, mean age 63 years) for an overall prevalence of 3.81%. The
corresponding prevalence in the same calendar year among males and females was
5.22% and 2.41%, respectively. The prevalence additionally increased according
to age group, reaching 11.65% among individuals at least 65 years old.  We additionally identified 14,892 incident
cases in 2012 for an overall incidence rate of 3.28 per 1,000 person-years. The
corresponding incidence rates among men and women in 2012 were 4.32 and 2.25,
respectively, per 1,000 person-years. Both the prevalence and incidence of gout
increased substantially over the study period (Figures 1a and 1b). All secondary case definitions of gout showed
similar levels of this increasing trend.

Conclusion:
These findings from BC, representative of the Canadian general population,
indicate that the incidence and prevalence of gout are substantial and have
increased over the past several decades.

 


Figure
1a
. Annual trends of standardized prevalence (%) in
BC, Canada.

Figure
1b.
Annual trends of standardized incidence (per
1,000 person-years) in BC, Canada.


Disclosure: S. K. Rai, None; J. A. Avina-Zubieta, None; N. McCormick, None; M. De Vera, None; K. Shojania, None; E. C. Sayre, None; H. K. Choi, None.

To cite this abstract in AMA style:

Rai SK, Avina-Zubieta JA, McCormick N, De Vera M, Shojania K, Sayre EC, Choi HK. Rising Incidence and Prevalence of Gout in the Canadian General Population [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/rising-incidence-and-prevalence-of-gout-in-the-canadian-general-population/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rising-incidence-and-prevalence-of-gout-in-the-canadian-general-population/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology